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Abstract: Cardiovascular disease, the leading cause of death worldwide, is predominantly associated
with atherosclerosis. Atherosclerosis is a chronic inflammatory disease characterised by the narrowing
of large to medium-sized arteries due to a build-up of plaque. Atherosclerotic plaque is comprised
of lipids, extracellular matrix, and several cell types, including endothelial, immune, and vascular
smooth muscle cells. Such narrowing of the blood vessels can itself restrict blood flow to vital organs
butmost severe clinical complications, including heart attacks and strokes, occur when lesions rupture,
triggering the blood to clot and obstructing blood flow further down the vascular tree. To circumvent
such obstructions, percutaneous coronary intervention or bypass grafts are often required; however,
re-occlusion of the treated artery frequently occurs. Neuropilins (NRPs), a multifunctional family of
cell surface co-receptors, are expressed by endothelial, immune, and vascular smooth muscle cells
and are regulators of numerous signalling pathways within the vasculature. Here, we review recent
studies implicating NRP2 in the development of occlusive vascular diseases and discuss how NRP2
could be targeted for therapeutic intervention.
Keywords: neuropilin; atherosclerosis; inflammation; endothelial cell; macrophages; vascular smooth
muscle; cell surface receptor; drug target
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide, costing the National
Health Service in England an estimated £7.4 billion per year [1]. CVD is predominantly associated
with atherosclerosis, which can typically be classified into four main stages (Figure 1).
(1) Firstly, endothelial cell (EC) activation, commonly occurring in areas of aberrant blood flow,
stimulates the accumulation and oxidation of low-density lipoprotein (LDL) within the vessel wall [2].
Oxidised LDL and adhesion molecules secreted from activated ECs attract monocytes from the blood
into the subendothelial intima where they di↵erentiate into macrophages, which ingest lipoproteins
and subsequently become foam cells [2]. These deposits, referred to as fatty streaks, begin to develop
in childhood [3].
(2) In humans, vascular smooth muscle cell (VSMC) accumulation in the intimal space occurs in
utero in conserved locations susceptible to the development of atherosclerotic plaque, including branch
sites and areas of turbulent blood flow [4]. In response to inflammatory mediators and cytokines,
VSMCs migrate, proliferate, and secrete extracellular matrix (ECM) proteins [2]. ECs have also been
reported to lose cell-cell interaction and undergo endothelial to mesenchymal transition (EndoMT),
contributing to plaque growth [2]. By the age of puberty, more than 50% of children present fibrous
atherosclerotic plaque, containing hyperplastic VSMCs [3].
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(3) In progressing plaques, macrophages and VSMCs become necrotic, releasing lipids which
accumulate within the centre of the lesion to form the necrotic core [2]. VSMCs migrate and proliferate to
create the fibrous cap and secrete ECM components providing stability to the atherosclerotic lesion [2].
Lymphangiogenesis and neovascularisationmay also occur at this stage [5,6]. By our late 20s, almost a third
of us have well-developed lesions with large lipid-filled necrotic cores and thick fibromuscular caps [3].
(4) In advanced plaque, the fibrous cap may rupture and trigger the blood to clot—this can lead to
complications including heart attack and stroke bymiddle age [3,7]. Percutaneous coronary intervention
and bypass grafts are sometimes required to restore blood flow; however, such interventions themselves
may lead to further clinical complications [8,9]. In recent years, numerous studies have revealed that
ECs, macrophages, and VSMCs undergo extensive phenotypic changes in diseased blood vessels, often
in response to lipid and pro-inflammatory cytokine exposure [10–22]. These phenotypic changes can
both promote and attenuate the progression of occlusive vascular diseases including atherosclerosis,
interventional restenosis, and transplant vasculopathy [10–22].
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macrophages uptake lipid to form foam cells leading to fatty streak formation. ECs undergo EndoMT. 
These two initial stages can occur by puberty. (3) Extracellular lipids released from dead and dying 
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a third of us have well-developed lesions. (4) Finally, chronic inflammation and necrosis can lead to 
plaque rupture. Subsequent thrombosis may obstruct blood flow, often resulting in adverse clinical 
outcomes, including heart attack and stroke. Such clinical complications associated with complex 
atherosclerotic lesions can occur by middle age [2,3,5,6]. 
Neuropilin-1 (NRP1) and its closely related family member NRP2, are transmembrane co-
receptors, which are devoid of kinase activity [23–25]. Both NRP family members are expressed by a 
wide variety of cell types [23–25]. Although NRPs are commonly found at the cell surface, they have 
also been reported within the mitochondria [26,27] and nucleus [28]. NRPs were first implicated in 
neuronal guidance, vasculogenesis and angiogenesis in the embryo via mediating signalling 
pathways driven by class 3 Semaphorins (SEMA3s) and Vascular Endothelial Growth Factor (VEGF), 
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Figure 1. Four main stages of atherogenesis. (1) In response to endothelial cell (EC) activation, circulating
monocytes adhere to the vascular wall and infiltrate the intima. In the intima, monocytes mature to
macrophages and uptake lipids to become foam cells. (2) Vascular smooth muscle cells (VSMCs) migrate,
proliferate, and secrete extracellularmatrix (ECM) proteins. VSMCs andmacrophages uptake lipid to form
foam cells leading to fatty streak formation. ECs undergo EndoMT. These two initial stages can occur by
puberty. (3) Extracellular lipids released from dead and dying VSMCs andmacrophages accumulate at the
centre of the plaque to form the necrotic core. VSMCs on the luminal side of the vessel wall secrete ECM,
forming the fibrous cap, and provide stability to the lesion. Neovascularisation and lymphangi genesis
may also occur at this stage. By our late 20s, almost a third of us have well-developed lesions. (4) Finally,
chronic inflammation and necrosis can lead t plaque rupture. Subsequent thrombosi may obstruct
blood flow, often resulting in adverse clinical outcomes, including heart attack and stroke. Such clinical
complications associated with complex atherosclerotic lesions can occur by middle age [2,3,5,6].
Neuropilin-1 (NRP1) and its closely related familymemberNRP2, are transmembrane co-receptors,
which are devoid of kinase activity [23–25]. Both NRP family members are expressed by a wide variety
of cell types [23–25]. Although NRPs are commonly found at the cell surface, they have also been
reported within the mitochondria [26,27] and nucleus [28]. NRPs were first implicated in neuronal
guidance, vasculogenesis and angiogenesis in the embryo via mediating signalling pathways driven by
class 3 Semaphorins (SEMA3s) and Vascular Endothelial Growth Factor (VEGF), respectively [25,29–32].
However, NRPs are nowknown topartnerwith awidevariety of transmembrane receptors and therefore
modulate numerous signalling pathways [23,24], including those activated by Epidermal Growth Factor
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(EGF) [33], Fibroblast Growth Factor (FGF) [34], Hepatocyte Growth Factor (HGF) [35], Insulin-like
Growth Factor (IGF) [36], Platelet-Derived Growth Factor (PDGF) [37,38] and Transforming Growth
Factor beta (TGF ) [39]. As a result, NRPs mediate multiple cellular processes, and dysregulation
of their activity has been implicated with several pathological conditions [23,38,40–42]. NRPs are
expressed by ECs [31], leukocytes [24] and VSMCs [38,40,43–45] within the vasculature, and are
emerging as multifaceted regulators of signalling pathways associated with CVD [23].
Both NRP family members share the same basic structure consisting of an extracellular domain
comprised of two CUB (complement C1r/C1s, Uegf, Bmp1) subunits (a1, a2), a factor V/VIII coagulation
factor homology subunit (b1, b2) and aMAM (meprin, A-5 protein, receptor protein-tyrosine phosphatase
mu) subunit (c), a transmembrane domain, and a short cytoplasmic domain (Figure 2) [24,46,47]. NRPs
can also be found in soluble forms created by alternative splicing [47] or by extracellular domain shedding
of the transmembrane proteins [27] (Figure 2). The a1/a2/b1 subunits have long been known to interact
with class 3 Semaphorins to regulate neurogenesis while the b1/b2 domains bind to VEGF-A and VEGF-C
to mediate angiogenesis [48]. Although less well characterised, VEGF-D has also been described to
interact with NRP2 in the context of lymphangiogenesis [49]. The extracellular c domain was thought to
be important for NRP oligomerisation with other cell surface receptors [48,50]; however, a recent study
has challenged this function [51]. The intracellular PDZ (PSD95, Dlg, ZO-1) binding motif facilitates
association with PDZ domain-containing proteins, including GIPC (RGS-GAIP-interacting protein),
which can directly mediate signalling in ECs [52–54].
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Figure 2. Basic Neuropilin (NRP) structure. NRPs have an extracellular domain comprised of two
tandem CUB (complement C1r/C1s, Uegf, Bmp1) subunits (blue circles), two factor V/VIII coagulation
factor homology domains (pink squares) and a MAM (meprin, A-5 protein, receptor protein-tyrosine
phosphatase mu) subunit (orange octagon), a transmembrane domain, and a short cytoplasmic
domain [24,46,47]. NRPs can also be found in soluble forms [27,47]. The a1/a2/b1 subunits interact
with class 3 Semaphorins, the b1/b2 subunits interact with VEGF-A, -C, and -D, and the c subunit
is thought to be involved in oligomerisation with other receptors [48–50]. The PDZ binding motif
facilitates association with proteins containing a PDZ (PSD95, Dlg, ZO-1) domain, including GIPC
(RGS-GAIP-interacting protein) [52–54].
Despite being 44% identical at the amino acid level, NRP1 and NRP2 exhibit distinct expression
patterns and ligand preferences in vivo [46,55]. For example, 1 predomina tly binds to
VEGF-A165 to mediate angiogenesis [56–58] in vascular ECs, whereas NRP2 i teracts with VEGF-C
to regulate lymphangiogenesis [46,59–61]. NRP1 and NRP2 knockout mice also display disparate
phenotypes—while NRP1 knockout is embryonic lethal at E10.5 to E13.5 due to a spectrum of
cardi vascular and neuronal defects, NRP2 knockout embryos remain viable b t exhibit decreased
numbers of lymphatic capillaries, as well as abnormal guidance and arrangement of cranial and spinal
erves [30,32,61,62]. NRP1 and NRP2 double knockout mice display even greater vascular defects a
die in utero at E8.5 with large areas in the yolk sac totally void of blood vessels [63]. Furthermore, NRP1
and NRP2 are regulated by separate stimuli which elicit di↵erent cellular responses. For example,
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in smooth muscle cells (SMCs), while NRP1 appears to be upregulated by FGF and PDGF [38,64],
which promote migration and proliferation [65,66], NRP2 is induced by Tumour Necrosis Factor alpha
(TNF↵) and Interleukin-1 beta (IL-1 ), which elicit a pro-inflammatory response [66–70]. Together,
these observations suggest that NRP1 and NRP2 have unique as well as overlapping functions. NRP1
is known to mediate vascular disease associated TGF  and PDGF signalling as reviewed by Kofler and
Simons [23]; however, the role of NRP2 is less well defined. Here, we discuss recent studies implicating
NRP2 in the development of occlusive vascular diseases and consider how NRP2 could be targeted for
therapeutic intervention.
2. Endothelial Cell Dysfunction
Disturbed blood flow results in EC activation, which refers to the attainment of a pro-inflammatory
and pro-coagulant state associated with the initiation of atherogenesis (Figure 1). Although much is
known regarding NRP1 function in EC migration, proliferation, and permeability [23,71,72], the role of
NRP2 in EC dysfunction remains unclear. However, there is building evidence implicating EC-derived
NRP2 in EndoMT, lymphangiogenesis, and neovascularisation. These processes are all associated with
the development of occlusive vascular diseases.
2.1. Endothelial to Mesenchymal Transition
Following their activation, ECs further contribute to neointimal thickening in atherosclerosis by
undergoing EndoMT. EC lineage tracing studies have shown that, in response to injury or inflammation,
ECs lose the expression of EC markers such as VE-cadherin and CD31, and acquire myofibroblast
markers, including ↵-smooth muscle actin, N-cadherin and calponin [17]. As well as the acquisition of
a more contractile phenotype, EndoMT is accompanied by loss of cell-cell/cell-ECM contact, increased
migratory activity, and synthesis of ECM components [17].
Both in vitro and in vivo studies have revealed that activation of the TGF  signalling pathway is
a major inducer of EndoMT [17,73]. In mouse pancreatic ECs, TGF -induced EndoMT upregulates
miR27 levels, which post-transcriptionally suppresses NRP2 expression [74]. Since NRP2 deficiency
promotes SMC contractility [43,70,75], the authors hypothesise that miR27-induced silencing of NRP2
activity is required for the transition to a more contractile phenotype [74]. However, the authors
observed that miR27 also targets ELK1, a myogenic transcription factor which acts as a competitive
inhibitor of serum response factor (SRF). Many contractile genes are regulated by SRF, a transcription
factor which binds to CC(A/T-rich)6GG (CArG) cis-elements of all known CArG dependent contractile
SMC genes, including ACTA2, CNN1, TAGLN andMYH11 [18]. Therefore, miR27-induced silencing of
NRP2 may not be causally linked to the transition to a more contractile phenotype in EndoMT but
rather the modulation of contractile genes by SRF.
Indeed, Grandclement et al. found that transfecting a colon cancer epithelial cell line (HT29 cells)
with plasmids encoding NRP2 induces an elongated fibroblast-like cell morphology reminiscent of
mesenchymal cells [39]. The authors go on to show that NRP2 expression in HT29 cells activates
TGF  signalling, leading to constitutive phosphorylation of the Smad2/3 complex and inhibition of
E-cadherin expression (an epithelial cell marker) and upregulation of vimentin expression (a protein
specific to mesenchymal cells) [39]. The group used surface plasmon resonance to demonstrate that
NRP2 binds to TGF 1 and performed co-immunoprecipitation to show that NRP2 complexes with
TGFBR1 in HT29 cells. Pharmacological inhibition of TGFBR1 restored epithelial cell markers and
inhibited NRP2-induced mesenchymal gene induction in HT29 cells [39]. Therefore, NRP2 may
positively regulate EndoMT by directly binding to TGF 1 and complexing with TGFBR1 (Figure 3a).
2.2. Lymphangiogenesis and Neovascularisation
Lymphatic vessels (LVs) are found in adventitial and intraplaque regions of human atherosclerotic
carotid arteries [76]. There is evidence suggesting LVs are essential for the removal of cholesterol,
leukocytes, and cytokines from atherosclerotic blood vessels [5]. As a result, LVs may help reduce
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plaque burden. In atherosclerotic lesion sites, local environmental cues also stimulate angiogenesis
from pre-existing vasa vasorum, a network of small blood vessels that supply the walls of large
arteries. Intraplaque neovascularisation facilitates the supply of nutrients and O2 to atherosclerotic
lesions supporting plaque growth. However, dysregulated neo-capillary development may promote
intraplaque haemorrhages increasing the chance of plaque rupture.
NRP2 is highly expressed in lymphatic ECs and in the stroma of many types of tumour, where it
supports lymphangiogenesis and neovascularisation [77]. Furthermore, NRP2 deficiency suppresses
lipopolysaccharide (LPS)-induced lymphangiogenesis [78] and VEGF-induced neovascularisation in
the retina [79]. These observations suggest that NRP2 may play a role in lymphangiogenesis and
neovascularisation associated with occlusive vascular diseases. In 2006, in vitro studies demonstrated
that NRP2 interacts with VEGFR2 and VEGFR3 to promote human EC survival and migration induced
by VEGF-A and VEGF-C [80]. Furthermore, in 2006, Kärpänen et al. found that NRP2 interacts with
VEGF-C and VEGF-D and complexes with VEGFR3 in lymphatic ECs [49]. A couple of years later,
Caunt et al. found that tumour associated lymphangiogenesis was reduced by blocking VEGF-C–NRP2
binding [59]. Using transgenic mice, Xu et al. demonstrated that the sprouting of lymphatic ECs
in response to VEGF-C is mediated by NRP2 complexing with VEGFR3 [81] (Figure 3b). Further
studies showed that TGF -mediated activation of TGFBR1 and TGFBR2 promotes dermal lymphatic
EC sprouting by upregulating VEGFR3 and NRP2 expression [82].
NRP2 is also known to regulate lymphangiogenesis and angiogenesis via VEGF independent
mechanisms. Indeed, recent studies have revealed that NRP2 interacts with integrins, a family of
widely expressed cell adhesion receptors [83–85]. In particular, NRP2 has been shown to complex
with integrin ↵5 [83] and ↵9 [84]—adhesion molecules which bind to proteins containing an arginine,
glycine, and aspartate (RGD) amino acid sequence [85]. The RGD motif is common to numerous
ECM proteins which display enhanced deposition during vascular remodelling responses, such as
fibronectin, fibrinogen, and vitronectin [85]. Interestingly, EC integrin ↵5 1 interaction with fibronectin
is implicatedwith activation of theCVD-associatedNFkB signallingpathway [86–88] and atherosclerotic
angiogenesis [89]. Cao et al. demonstrated that NRP2 expressed on cancer cells interact with ↵5
integrins on ECs to promote vascular adhesion and extravasation using renal and pancreatic cell
cancer models [83]. Activation of the NFkB signalling pathway is responsible for the transcriptional
induction of pro-inflammatory cytokines, chemokines, adhesion molecules, and genes which alter
the composition of the ECM. The development of numerous cancers as well as vascular diseases are
strongly associated with the expression of NFkB target genes. Therefore, it is worthwhile investigating
whether the modulation of EC adhesion and migration on fibronectin by recycling integrin ↵5 via
NRP2, as described in Alghamdi et al., is NFkB-dependent [90]. Furthermore, Ou et al. observed that,
in colorectal carcinoma, expression of NRP2 in lymphatic ECs significantly increases their migration,
sprouting, and tubulogenesis capacity via binding to integrin ↵9 1 and stimulating activation of
the FAK/ERK signalling pathway [84] (Figure 3c). NRP2 may therefore modulate integrin-mediated
vascular cell-ECM and cell-cell interactions to regulate signalling pathways, and fine-tune cell function
to local environmental conditions.
NRP2 is also thought to play a role in blocking lymphangiogenesis and neovascularisation
while promoting vascular permeability through interacting with Plexin receptors and binding to
SEMA3s [91–98] (Figure 3d). There is evidence suggesting that SEMA3s may compete with VEGF
family members for binding to NRP2 [91,97]. However, other studies have demonstrated that NRP2
complexes with Plexin receptors to promote SEMA3 driven R-Ras signalling, leading to the inactivation
of  1-integrin and dissociation from the ECM [93,98]. As a result, SEMA3s are thought to inhibit
angiogenesis via impairing EC adhesion after binding to NRP2. SEMA3G stimulation, a ligand known
to bind to NRP2, of EC and SMC co-cultures leads to rapid EC detachment [95]. NRP2 interaction with
Sema3F and Plexin A1 has also been shown to inhibit PI-3K and mTORC signalling attenuating EC
proliferation and survival [94]. There is evidence suggesting that loss of endogenous Sema3F activity is
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responsible for enhanced vascular permeability, inflammation, and lymphedema observed in inflamed
ears of NRP2 deficient mice compared to wild type controls [96].
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NRP2 complexing with VEGFR-3 [81]. (c) VEGF/NRP2 signalling facilitates ↵6 1 integrin eng gement
with ECM compo ents. Signalling through this integrin activates a FAK/ERK driven signalling resulting
in ECmigration, sprouting and lymphangiogenesis [84] (d) NRP2 complexes with Plexins to drive SEMA3
driven R-Ras signalling leading to loss of EC-ECM/VSMC adhesion which leads to increased vascular
permeability [93,95]. NRP2/Sema3F/Plexin A1 inhibits PI-3K and mTORC signalling attenuating EC
proliferation and survival [94]. The NRP2/SEMA3/Plexin complexes are implicated in downregulating
angiogenesis and lymphangiogenesis, while promoting vascular permeability [91–97]. (e) NRP2 binding
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Finally, NRP2 also binds to Angiopoietin-like 4 (ANGPTL4), a multifunctional protein involved
in wound healing and modulation of vascular permeability. The resulting activation of the complex
leads to the activation of the RhoA/ROCK signalling pathway, the dissociation of EC-EC junctions, and
subsequent retinal vascular leakage [99] (Figure 3e).
With these observations in mind, it is tempting to speculate that NRP2 influences changes in EC
behaviour associated with CVD. However, whether it is beneficial to target EC-derived NRP2 to treat
occlusive vascular diseases is most likely context dependent. Therefore, more studies are required to
further our understanding of EC-derived NRP2 in the context of CVD.
3. Monocyte Recruitment and Macrophage Activity
3.1. Monocyte Recruitment
Atherogenesis involves the recruitment of circulatingmonocytes to thevascularwall. Once adhered
to the vascular wall, monocytes di↵erentiate into macrophages, ingest lipoproteins, and subsequently
become foam cells (Figure 1) [100]. This process helps clear atherogenic lipoprotein complexes from
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the blood vessel; however, excessive oxLDL uptake has adverse e↵ects [100]. Lipid-rich foam cells
secrete pro-inflammatory cytokines, elicit pro-apoptotic pathways, and inhibit clearance of dying cells
leading to lesion growth and destabilisation of the necrotic core [100]. Interestingly, leukocytes, as well
as ECs and VSMCs, express integrins, which are known to interact with NRPs [85,101]. As activated
ECs [82] and VSMCs [38,68–70] upregulate NRP2 expression, NRP2 may mediate monocyte adhesion
to the vascular wall by interacting with integrins expressed by monocytes.
3.2. Macrophage Activity
Lipid-laden macrophages are a key feature of atherosclerotic lesions. Plaque resident macrophages
originate from numerous sources including circulating bonemarrow-derivedmonocytes, local proliferation
of tissue-residentmacrophages, and transdifferentiationofVSMCs [11,12]. Indeed, single-cell transcriptomic
analysis revealed that macrophages within atherosclerotic plaque are extremely heterogenous—this
observation may help explain how they performmultiple functions, which influence atherogenesis and
lesion stability [11,12].
Interestingly, NRP2 is not initially detectable in monocytes but becomes highly expressed as they
differentiate into macrophages [102,103]. NRP2 is highly and broadly expressed by different macrophage
subsets, including alveolar, bronchial, peritoneal, and intravascularmacrophages [24,102,104]. This observation
suggests that NRP2may play an important role in macrophage function.
Roy et al. observed that NRP2 expression in macrophages correlates with their ability to perform
efferocytosis, a process by which apoptotic cells are engulfed and cleared by macrophages [103]. NRP2
inhibition using siRNA attenuated phagosome maturation without affecting uptake of phagocytic cargo
in macrophages derived from human peripheral bloodmononuclear cells treated with colony-stimulating
factor (CSF) [103]. Furthermore, NRP2 knockout specifically in bone marrow-derived macrophages
attenuated the clearance of apoptotic cells in vitro [103]. These observations were validated in vivo; in the
same study, they demonstrated that the ablation of NRP2 in tumour-associated macrophages (TAMs)
impaired the clearance of apoptotic tumour cells, resulting in elevated levels of necrosis within the
tumour core [103]. Interestingly, the group also observed downregulation of immunosuppressive genes
(IL4, IL10, MMP11, MMP13) and upregulation of immunostimulatory genes (IL12a, IFNb, Gr-K, Gr-F)
following NRP2 deletion in TAMs [103] (Figure 4). Therefore, it is tempting to speculate that NRP2
enables macrophages to efferocytose without causing an immune response against apoptotic tumour cell
components. It would be worthwhile investigating whether NRP2+macrophages, in a similar manner,
help clear lipids and dying cells from atherosclerotic plaque without eliciting inflammation. If so, NRP2+
macrophages could promote atherosclerotic plaque regression and stability.
Intriguingly,NRP2 is oneof only sixproteinswhich canbepost-translationallymodifiedby theaddition
of polysialic acid (polysialylation) and removal of polySia enhances phagocytosis of Klebsiella pneumoniae
by peritoneal macrophages [105]. Furthermore, peritoneal macrophages isolated from inflamed sites
express NRP2 which has not been modified by polysialylation but start to re-express polySia on NRP2
after 24 h in culture when removed from the inflammatory environment [105]. This observation suggests
NRP2 facilitates phagocytosis in peritoneal macrophages although a direct causal link has not yet been
demonstrated (Figure 4). Therefore, in the context of atherosclerosis, loss of polySia onmacrophage-derived
NRP2 may facilitate phagocytosis of lipids and apoptotic cells.
PolysialylatedNRP2 is shed bymicroglia in response to LPS-induced conversion to a pro-inflammatory
phenotypic state (Figure4). LPSstimulationof culturedmicroglial cells induces translocationofpolysialylated
NRP2 from Golgi-confined intracellular pools to the cell surface before polysialylated NRP2 is cleaved and
shed into the supernatant [27] (Figure 4). Because polysialylatedNRP2 is presented at the cell surface during
early LPS challenge it may mediate interactions with signalling proteins which promote a pro-inflammatory
phenotype; however, this is yet to be investigated (Figure 4). Conversely, polysialic acid is known to inhibit
inflammatory responses by binding to sialic acid-binding immoglobulin-like lectin 11 receptor (SIGLET1) on
humanmyeloid cells [106]. Polysialic binding to SIGLET1 initiates recruitment of cytoplasmic phosphatases
toblock signal transduction throughdephosphorylationof signallingmolecules [106]. Therefore, polysialated
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soluble NRP2may act as an anti-inflammatory mediator [107] (Figure 4). Soluble forms of NRP2 are also
known to act as decoy receptors. For example, a soluble form of NRP2 has been shown to scavenge VEGF-C
and inhibit pathological NRP2/VEGF-C signalling in a prostate cancer cell line [108]. Further studies are
required to elucidate the role of macrophage-derived NRP2, including post-translationally-modified, full
length, and soluble isoforms, in phagocytosis and inflammation associated with CVD.
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phagocytosis [105]. In tumour-associatedmacrophages (TAM ) (pink boxes), NRP2 facilitates efferocytosis
whilst promoting the ex ression of pro-inflammatory genes [103]. In microglia (blue boxes), following
LPS challenge, polysialylated NRP2 rapidly translocates to the cell surface before being shed from the
cells [27]. Soluble polysialylated NRP2 may have an immunosuppressive role by binding to SIGLET to
attenuate activation of pro-inflammatory signalling pathways [106,107]. However, polysialylated NRP2
at the cell surface may facilitate protein interactions to promote pro-inflammatory signalling.
4. VSMC Phenotypic Switching
In recent years, numerous studies have demonstrated that VSMCs play a substantial role in
atherosclerosis [18]. In the healthy blood vessel, VSMCs predominantly exhibit a quiescent “contractile”
phenotype but can switch to a more active “synthetic” state which exhibits pronounced migratory
and proliferative activity [18]. Upon insult, VSMCs downregulate the expression of contractile VSMC
markers and upregulate genes required for vascular r modelling including cytokines, adhes onmolecules,
and proteins which alter the omposition of the ECM [18]. VSMCs can also express markers typically
associatedwithother cell types includingmacrophages,myofibroblasts,MSCs, andosteochondrocytes [18].
Strikingly, genetic lineage tracing studies have shown that up to 90% of plaque-resident cells are
VSMC-derived [15,16].
4.1. NRPs are Expressed by Cardiovascular Precursor Cells
Ding et al. demonstrated that inmurine embryonic stem cells (mESCs), upon BMP4 stimulation, NRPs
are often co-expressed with Brachyury, a critical mesoderm inducing factor. NRP2 expression is induced in
mesodermal precursor cell subpopulations capable of differentiating into cardiomyocytes, endothelium,
and VSMCs. By inhibiting NRP2 expression in mESCs, the group demonstrated that NRP2 is functionally
required for differentiation towards endotheliumandVSMCsbut not toward cardiomyocytes [109]. A study
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assessing the onset of NRP2 expression in early chick embryos supports this in vitro finding. In the chick
embryo, NRP2 expression is found in cardiovascular precursor cells derived from the blood islands,
primitive streak, and lateral plate mesoderm [110]. Additionally, during avian blood vessel development,
NRP1 is predominantly expressed in the arterieswhereasNRP2 is expressed in the veins [110]. Furthermore,
by crossing mice containing Cre recombinase driven by the NRP2 locus with a ROSA26-LacZ reporter line,
researchers have demonstrated that at E12.5, NRP2 is expressed mainly in the venous vasculature, while
NRP1 expression is more arterial [111]. Interestingly, in vitro analyses of rabbit VSMCs demonstrated that
venous VSMCs display a more de-differentiated phenotypic state and exhibit increased proliferative and
synthetic activity in comparison to arterial VSMCs [112].
As cardiovascular precursor cells differentiate towardVSMCs, NRP2 expression is lost [109]. However,
NRP2 expression can be re-induced inVSMCs in response to insult [38,67]. With these observations inmind,
it is tempting to speculate that NRP2 marks a more dedifferentiated VSMC—a hallmark of many occlusive
vascular diseases. In support of this theory, NRP2 promotes stem-like traits in breast cancer cells via
VEGF-driven signalling [113]. Importantly, although the analysis is not yet peer-reviewed, new single-cell
transcriptomic data of human atherosclerotic plaque also implicates NRP2 in VSMC transdifferentiation
within the core [42] (Figure 5). Itwould, therefore, be of great scientific and therapeutic interest to investigate
whether NRP2 expression marks a more plastic VSMC state.
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response to injury [38,114] and pro-inflammatory stimuli [69,70] via Smad3 transcription factor binding
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4.2. Nrp2 is Re-Expressed in Mature VSMCs in Response to Injury/Inflammation
VSMCs do not appear to express NRP2 under quiescent conditions [43] but increased levels of
NRP2 have been observed in SMCs in response to injury [38,41,114] and inflammatory stimuli [66–70]
(Figure 5). Elevated NRP2 expression has been detected within VSMCs following balloon angioplasty
in a rat model of vascular injury [38]. This increase was particularly noticeable at time points known
to correlate with increased levels of pro-inflammatory cytokines within the vessel wall [115,116].
Downregulation of NRP2 using shRNA adenoviral vectors resulted in a significant reduction of
neointimal hyperplasia following balloon angioplasty, supporting a role for NRP2 in disease-associated
vascular remodelling [38]. NRP2 inhibition was also shown to reduce PDGFbb-mediated migration
and proliferation of rat VSMCs in vitro as well as injury-induced rat VSMC proliferation in vivo [38]
(Figure 5). However, NRP2 levels were not influenced by PDGFbb stimulation. Xie et al. observed
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that NRP2 expression in VSMCs in response to injury is induced by p-SMAD3 binding to the 50
untranslated region (UTR) of NRP2, between +51 to +78bp from the transcriptional start site (TSS) [41].
Importantly, using siRNA to inhibit NRP2 activity, the group demonstrate that, in primary human
aortic SMCs, NRP2 positively regulates TGF -induced VSMC proliferation and migration as well as
cholesterol-induced conversion to a macrophage-like (CD68+) phenotype [41] (Figure 5).
Numerous studies have demonstrated that, in response to inflammation, VSMCs downregulate the
expression of contractile genes—a process associated with plaque instability [18]. In healthy adult mice,
NRP2 is expressed by SMCs in the bladder and gut but not in the vasculature, heart, or skeletalmuscle [43].
Interestingly, SMC-specific knockout of NRP2 promotes the contractility of SMCs in the bladder and
gut via mediating activation of the RhoA/ROCK signalling pathway [43,70,75] (Figure 5). This finding
suggests that injury/inflammation-induced NRP2 upregulation by VSMCs may be linked to loss of the
contractile VSMC state. However, no studies to date have investigated if disease-associated loss of VSMC
contractility is causally linked to NRP2 expression. Additionally, while NRP2 expression is upregulated
by pro-inflammatory stimuli known to activate the NFkB signalling pathway [68–70], contractile VSMC
genes are downregulated [117–120], suggesting NRP2 may not directly cause loss of VSMC contractility.
Activation of the NFkB signalling pathway in VSMCs eventuates in NFkB (p65 subunit) binding to the
MYOCD promoter, decreasing the expression of MYOCD and MYOCD-dependent contractile genes
(e.g., ACTA2, TAGLN, and MYH11) [117–120].
5. NRP2 is an Attractive Therapeutic Target
NRP2 is upregulated by vascular cell types in response to injury/inflammation and is involved in
numerous processes associated with the development of occlusive vascular diseases. Currently, many
molecules linked to CVD, including various transcription factors, are poor drug targets. Because cell
surface receptors are more easily targeted, NRP2 could be a novel therapeutic candidate or biomarker
to treat or detect diseased blood vessels.
A variety of methods to inhibit VEGF-C/NRP2-driven signalling have been explored [59,108,121].
VEGF-C/NRP2 driven signalling promotes EC migration and survival as well as angiogenesis and
lymphangiogenesis (Figure 3)—processes associated with vascular neointimal hyperplasia and atherosclerosis.
Therefore, inhibitingVEGF-C/NRP2driven signalling couldpotentially beused therapeutically in the treatment
of occlusive vascular diseases. Monoclonal antibodies targeting the VEGF-C binding domain of NRP2 have
been developed andwere able to decrease the number of tumour-associated lymphatic vessels andmetastasis
in animal xenograft experiments [59]. Furthermore, a soluble splice variant of NRP2, s9NRP2, has been
shown to scavenge VEGF-C away from the functional complex and inhibit the formation of prostatospheres
by a human prostate carcinoma cell line [108], suggesting that s9NRP2 could potentially be used to inhibit
pathological VEGF-C/NRP2 signalling in prostate cancer [108]. In 2020, Said et al. have reported the discovery
of a novel benzamidine-based inhibitor that functions via competitive inhibition of VEGF-C binding to
NRP2 [121]. To date, no other pharmacological inhibitors have been identified which target NRP2.
However, atherogenesis is complex and whether VEGF-C/NRP2-driven cellular responses prevent
or promote adverse clinical outcomes is most likely context-dependent. For example, local inhibition
of VEGF-C/NRP2 driven signalling may block a deleterious EC response to injury by attenuating EC
migration and survival and may, therefore, be a useful strategy to prevent re-occlusion of blood vessels
after surgical intervention. However, as NRP2 promotes lymphangiogenesis, which is important
for the removal of cholesterol, leukocytes, and cytokines from plaque, inhibiting NRP2 in advanced
atherosclerotic lesions may promote plaque growth and instability.
Additionally, becauseNRP2 promotes PDGFbb and TGF -induced VSMCmigration, proliferation,
and loss of SMC contractility, it may be beneficial to inhibit NRP2 as a therapeutic strategy to
treat occlusive vascular diseases. NRP2 could be inhibited by developing neutralising antibodies.
Promisingly, directly inhibiting PCSK9 (a protein which promotes levels of circulating LDLs) and
IL-1  (a pro-inflammatory cytokine) using monoclonal antibodies reduced the rate of cardiovascular
events, including heart attack and stroke, compared to placebo in patients [122–124]. However, NRP2
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inhibition may also have a deleterious e↵ect as NRP2 could potentially play an important role in the
phagocytosis of lipids by macrophages, helping clear atherogenic lipid complexes from the vascular
wall. Once again, it is important to emphasise that NRP2 inhibition may promote or prevent clinical
complications associated with CVD depending on the context. Consequently, a better understanding
of NRP2 function in CVD is of potential therapeutic interest.
As NRP2 is upregulated in the vasculature in response to injury and inflammation, it could be used
to help diagnose diseased arteries. For instance, Chen et al. developed an iodine-131 labelled NRP2
monoclonal antibody to image A549 xenograft tumours in mice by single-photon emission computed
tomography (SPECT) [125]. As SPECT is used clinically to visualise atherosclerotic plaques [126],
perhaps, a similar approach could be used to visualise obstructed blood vessels in patients.
6. Conclusions and Future Perspectives
To summarise, NRP2 is expressed by numerous cell types within the vasculature and plays
multifunctional roles in processes associated with the development of occlusive vascular diseases. Recent
studies implicate NRP2 in EndoMT, lymphangiogenesis, angiogenesis, monocyte recruitment, the ability
of macrophages to phagocytose, and VSMC plasticity. Consequently, NRP2 is likely to have complex
roles within atherosclerotic blood vessels and may function to both prevent and promote plaque stability
depending on the context. NRP2 is already targeted for cancer therapy [127]. Since cancer and occlusive
vascular diseases share many commonalities, including pronounced cell plasticity, migration, proliferation,
and inflammation [6], NRP2, an accessible cell surface receptor, may be a novel candidate for therapeutic
intervention. However, the role ofNRP2 inCVDremains enigmatic—adetailedmechanistic characterisation
of NRP2 function in CVD is required to develop efficient strategies to limit cardiovascular risk.
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